[VoiceOps] Phase III clinical trials of Kamailio DMQ

Thu Apr 1 15:36:25 EDT 2021

GMO?

On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <David.Hiers at cdk.com> wrote:

> No AI here...  This is classic, small-batch, hand-crafted, free-range,
> organic, gluten-free content.
>
>
> David
>
>
> -----Original Message-----
> From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov
> Sent: Thursday, April 1, 2021 12:18 PM
> To: Brandon Svec <bsvec at teamonesolutions.com>
> Cc: voiceops at voiceops.org
> Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
>
> Let me make sure I understand your question correctly: it is your belief
> or conjecture that this press release was automatically generated by a
> machine learning system?
>
> —
> Sent from mobile, with due apologies for brevity and errors.
>
> > On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com>
> wrote:
> >
> > GPT-3? Happy April Fools Day.
> >
> > Brandon
> >
> >> On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com>
> wrote:
> >>
> >> For immediate release:
> >>
> >> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
> >> with Posner | Palner Pharmaceuticals, are pleased to announce the
> >> eagerly anticipated start of Phase III clinical trials of Kamailio
> >> DMQ module replication.
> >>
> >> In this stage of the investigation of the promising replication
> >> scheme, which was developed in record time, DMQ will be tested in a
> >> rigourous, double-blind, controlled CI/CD process for large-scale
> >> efficacy and continually monitored for safety in shorter and longer
> terms.
> >>
> >> The now-concluded second phase established basic safety and Phase 2b
> >> entailed a dose-finding study for the optimal number of batched
> >> `dmq_usrloc` contacts per kilogram of cloud computing resource.
> >>
> >> The main cohort of the main sequence of the Phase III trial will
> >> enroll 380 randomly selected, statistically representative Floridian
> >> SIP registrars and
> >> 5700 SIP dialogs, also in the state of Florida. When asked about the
> >> disparity in the number of registrars versus dialogs, Alex Balashov
> >> of Evariste said, "It is reflective of the small number of SIP
> >> registrars in Florida; not to be indelicate, but consider the median
> age of the population."
> >>
> >> As previously remarked upon in proceedings of the World SIP
> >> Organisation (WSO), the choice of Florida as a venue attracted some
> >> questions. We asked Fred Posner of Posner | Palner about the clinical
> >> background informing this choice of replication study cohort:
> >>
> >> "Florida is a good place to find eventual consistency failures; the
> >> open climate and reluctance to accept traditional data integrity
> >> science would have sealed the deal, but when people started to drink
> >> bleach here, I saw an opportunity."
> >>
> >> Evariste and Posner | Palner are aiming for a US Food & Drug
> >> Administration EUA (Emergency Use Authorisation) for DMQ replication
> >> as a prophylactic data redundancy and failover measure to ward off
> >> the development of moderate to severe viral Sonus Haemorrhagic Fever
> symptoms.
> >>
> >> Phase II studies have painted a promising a picture of the DMQ
> >> architecture's ability to reduce moderate to severe symptoms and
> >> associated 28-day mortality by more than 90%, albeit over a small
> >> sample size and in enterprise patients with known pre-existing
> >> comorbidities such as Session Border Controller and BroadSoft
> >> Multi-System Inflammatory Syndrome.  Phase III trials seek to bolster
> >> quantums of broader efficacy, including efficacy for localised
> outbreaks of small to medium business softswitch.
> >>
> >> Of the control group, Balashov said, "They will receive a standard
> >> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
> >> confirmation messages. We proudly developed this approach in early
> >> 2020 in consultation with the highest levels of the Trump
> >> presidential administration; it is called TENP, or 'The Emperor's New
> >> Potion.' It is a successor to that administration's previous approved
> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
> >>
> >> Despite speculative autism and packet fragmentation claims by Florida
> >> Governor Ron DeSantis, Balashov was quick to provide reassurance
> >> about side effects from DMQ in the Phase III trial.
> >>
> >> "The incidence of severe allergies to plain-text UDP was within
> >> standard deviation over the mean for all insecure replication, and
> >> there's support for other transports on the way. Anyway, we have a
> >> robust adverse effects reporting system in our issue tracker and
> >> solid surveillance. Don't let partisan politics dissuade you from
> allowing request lines with the KDMQ method."
> >>
> >> Other industry sources have reported that DMQ is not the only
> >> replication investigation undertaken by Evariste and Posner | Palner,
> >> although it is the only prophylactic suitable for the early infection
> >> development and inflammatory phases of a broad class of SBC-complex
> >> syndromes typically afflicting service providers. A recent IETF
> >> preprint by the same authors has shown high-quality preliminary data
> >> suggesting statistically significant improvement in morbidity
> >> outcomes from Perimeta and Nokia via a later-stage therapeutic
> intervention with a monoclonal, monorepo Github cocktail administered
> intravenously.
> >>
> >>
> >> --
> >> Alex Balashov | Principal | Evariste Systems LLC
> >>
> >> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
> >> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
> >> _______________________________________________
> >> VoiceOps mailing list
> >> VoiceOps at voiceops.org
> >> https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
> ----------------------------------------------------------------------
> This message and any attachments are intended only for the use of the
> addressee and may contain information that is privileged and confidential.
> If the reader of the message is not the intended recipient or an authorized
> representative of the intended recipient, you are hereby notified that any
> dissemination of this communication is strictly prohibited. If you have
> received this communication in error, notify the sender immediately by
> return email and delete the message and any attachments from your system.
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://puck.nether.net/pipermail/voiceops/attachments/20210401/6d6dc0b5/attachment-0001.htm>